UCB and Domainex elaborate on cancer drug target collaboration

Belgian drugmaker UCB (Euronext Brussels: UCB) and Domainex, a UK-based drug discovery company, have jointly published the results of a collaboration in the field of cancer drug discovery.

Working together, the two companies have developed an experimental system to study the three-dimensional structure of Mitogen-activated protein kinase kinase (MAPKK, also known as MEK), a protein which is over-active in many human cancers. Using the high-resolution structural information, UCB scientists were able to design a novel class of molecules which inhibit MEK and which have the potential to combat cancer.

Used Domainex’ CDH technology